Dosing & Uses
Dosage Forms & Strengths
pseudoephedrine/desloratadine
tablet
- 120mg/2.5mg
- 240mg/5mg
Allergic Rhinitis/Congestion
Clarinex-D 12 hr: 1 tablet (2.5 mg desloratadine/120 mg pseudoephedrine) PO q12hr
Clarinex-D 24 hr: 1 tablet (5 mg desloratadine/240 mg pseudoephedrine) PO q24hr
Renal Impairment
Not recommended
Hepatic Impairment
Not recommended
Administration
Tablet should be swallowed whole and not broken, dissolved, or chewed
Dosage Forms & Strengths
pseudoephedrine/desloratadine
tablet
- 120mg/2.5mg
- 240mg/5mg
Allergic Rhinitis/Congestion
<12 years
- Safety and efficacy not established
≥12 years
- Clarinex-D 12 hr: 1 tablet (2.5 mg desloratadine/120 mg pseudoephedrine) PO q12hr
- Clarinex-D 24 hr: 1 tablet (5 mg desloratadine/240 mg pseudoephedrine) PO qDay
Renal Impairment
Not recommended
Hepatic Impairment
Not recommended
Administration
Tablet should be swallowed whole and not broken, dissolved or chewed
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Desloratadine
- Fever (12%)
- Irritability (12%)
- Headache (12%)
- Diarrhea (15-21%)
- Cough (11%)
- Upper respiratory tract infection (11-21%)
1-10%
Desloratadine
- Pharyngitis (4.1%)
- Dry mouth (3%)
- Myalgia (2.1%)
- Emotional lability (3%)
- Erythema (3%)
- Macopapular rash (3%)
- Dizziness (4%)
- Fatigue (2.1%)
- Somnolence (2.1%)
- Urinary tract infection (4%)
- Dyspepsia (3%)
- Insomnia (5%)
- Dysmenorrhea (2.1%)
Frequency Not Defined
Pseudoephedrine
- CNS (tremor, restlessness, etc)
- Insomnia
- Arrhythmia
- Hypotension
- Tachycardia
- Fatigue
- Rash
- Urticaria
- Anorexia
- Xerostomia
- Dysuria
- Polyuria
- Nausea
- Vomiting
- Ischemic colitis
Postmarketing Reports
Hypersensitivity reactions (eg, rash, edema, dyspnea, anaphylaxis)
CNS: Headache, somnolence, dizziness
Cardiovascular: Tachycardia
Neurologic: Movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures
Hepatic: Elevated liver enzymes and bilirubin, hepatitis (rare)
Skin reactions: Generalized exanthematous pustulosis, increased appetite
Warnings
Contraindications
Hypersensitivity; adverse reaction to sympathomimetics
Severe HTN, severe coronary artery disease
Concurrent MAO inhibitors, or within 2 wk of discontinuance of MAO inhibitors
Hepatic impairment
Urinary retention
Narrow-angle glaucoma
Clarinex-D 12 hr: also renal impairment
Cautions
Caution in renal impairment, HTN, diabetes mellitus, ischemic heart disease, increase IOP, hyperthyroidism, BPH
Concomitant antihistamines or decongestants (generally avoid)
Seizures and tachycardia reported
Pregnancy & Lactation
Pregnancy
The limited available data in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage; there are no adequate and well-controlled studies in pregnant women
The majority of studies examining use of pseudoephedrine in pregnancy did not find an association with increased risk of congenital anomalies; a few case-control studies conducted reported potential associations with isolated congenital disorders; however, methodological limitations of these studies made the interpretation of results unreliable
Reproductive potential
- There are no data available on human infertility associated with desloratadine, pseudoephedrine, or combination; there are no animal fertility studies with combination or pseudoephedrine alone
- Female: There were no clinically relevant effects of desloratadine on female fertility in rats
- Male: A male specific decrease in fertility occurred at an oral desloratadine dose of ≥12 mg/kg in rats (approximately 65 times the RHD); male fertility was unaffected at a desloratadine dose of 3 mg/kg (approximately 10 times the RHD)
Animal data
- Data on animal reproduction studies conducted with combination of desloratadine and pseudoephedrine or pseudoephedrine alone are also limited
- Desloratadine given during organogenesis to pregnant rats was not teratogenic at approximately 320 times that at recommended human daily oral dose (RHD) of 5 mg/day
- Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at AUC-based exposures of desloratadine approximately 230 times that at RHD
- Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F1 pups at exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD
Lactation
Desloratadine and pseudoephedrine both pass into breast milk; there are no sufficient data on effects of desloratadine on breastfed infant or effects of desloratadine on milk production
Pseudoephedrine has been reported to decrease milk production and to cause irritability in breastfed infants; the decision should be made whether to discontinue nursing or to discontinue drug, taking into account developmental and health benefits of breastfeeding, the nursing mother’s clinical need, and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Pseudoephedrine: Sympathomimetic; exerts decongestant action on nasal mucosa; stimulates the alpha-adrenergic receptors causing bronchodilation and vasoconstriction
Desloratadine: Selective histamine-1 receptor antagonist; inhibits histamine release from mast cells
Protein Binding
Desloratadine: 82-87%
Excretion
Pseudoephedrine: Urine
Desloratadine: Urine
Peak Plasma Time
Pseudoephedrine: 6-9 hr
Desloratadine: 4-7 hr
Peak Plasma Concentration
Pseudoephedrine: 363 ng/mL
Desloratadine: 1.09 ng/mL
AUC
Pseudoephedrine: 4,588 ng·hr/mL
Desloratadine: 31.6 ng·hr/mL
Metabolism
Pseudoephedrine: <1% metabolized in liver
Desloratadine: major metabolite of loratadine; extensively metabolized by glucuronidation to active metabolite 3-hydroxydesloratadine
Half-Life
Pseudoephedrine: 3-6 hr (urine pH 5); 9-16 hr (urine pH 8)
Desloratadine: 27 hr
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.